BLSM BlossomHill Therapeutics, Inc. revenue, earnings and financials
For the quarter ended June 30, 2026, BlossomHill Therapeutics, Inc. reported revenue of n/a, net income of −$23.8M and diluted EPS of −$8.75.
BLSM quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$23.8M, EPS −$8.75
- Quarter ended Jun 30, 2025: revenue n/a, net income −$13.2M, EPS −$5.51
BLSM balance sheet
- Jun 30, 2026: cash $95.4M, total assets $124M, total liabilities $42.1M, shareholders' equity −$175M
- Dec 31, 2025: cash $137M, total assets $163M, total liabilities $37.9M, shareholders' equity −$132M